Advances in endoscopic management of upper tract urothelial carcinoma

Upper tract urothelial carcinoma (UTUC) arises in the lining of the renal pelvis or ureter. It is less common than bladder cancer but can cause visible haematuria, obstruction, impaired kidney function and infection. Because symptoms may be intermittent, people in Australia can delay seeking review while the tumour remains small, which may support a kidney-preserving approach.

Endoscopic treatment has advanced from diagnostic ureteroscopy to a combined strategy of detailed mapping, laser resection and planned surveillance. Current flexible scopes, narrow-band imaging and high-powered lasers allow selected cancers to be treated through the natural urinary passage while preserving the kidney. The goal is not to replace every conventional operation, but to identify patients in whom organ-sparing care offers effective control with less recovery.

Selection remains highly individual. Tumour grade, size, location, spread and the patient’s renal function all affect the balance between endoscopic therapy and nephroureterectomy. Evidence is strongest for carefully selected cases, and a team involving urology, pathology and medical oncology can turn technical advances into a safer treatment plan.

Defining risk before selecting treatment

A suspected upper tract cancer usually begins with cross-sectional imaging and urine cytology, followed by ureteroscopy and tissue sampling when needed. Visible blood in the urine warrants prompt review even if it resolves; flank pain, fever or deteriorating renal function may indicate obstruction or infection. CT urography maps the collecting system, while cystoscopy checks the bladder because synchronous tumours can occur.

Risk stratification combines pathology with imaging and clinical factors such as hydronephrosis, multifocality, previous urothelial cancer and remaining kidney reserve. If prostate assessment is needed because of urinary symptoms or an incidental finding, PSA density stratification can refine prostate cancer risk; PSA does not diagnose UTUC. The key decision is whether the tumour can be removed completely by endoscopy without an unacceptable risk of residual disease or later recurrence.

Seeing and reaching the upper tract

Narrow-band imaging and image-enhanced ureteroscopy help reveal small or flat lesions that may be difficult to identify under white light. Flexible ureteroscopes provide access around the renal pelvis and calyces, while improved deflection, working channels and image processing support inspection, biopsy and treatment. Specialist interpretation remains essential because inflammatory and scar-related tissue can resemble malignancy.

Access and staging require careful planning. The team may use fluoroscopy, retrograde contrast imaging or CT urography to identify the tumour’s relationship to the renal pelvis and ureter. A temporary stent or catheter may be used to drain an obstructed system, while laser lithotripsy may be needed for associated stones. These steps can reduce infection and pressure-related kidney injury before definitive tumour treatment.

Resection techniques for kidney preservation

En bloc resection is increasingly used for selected tumours. The surgeon creates a fluid cushion between the tumour and deeper tissue, marks the intended margin and removes the lesion in one piece with a laser. This approach can provide a clearer specimen for pathology and may reduce residual tissue. Holmium:YAG and thulium fibre laser platforms offer different combinations of cutting, vaporisation and coagulation.

Not every lesion is suitable for en bloc removal. Piecemeal resection, basket extraction or focal ablation may be required for larger, multifocal or anatomically difficult tumours. The surgeon must treat the tumour base and obtain adequate tissue to determine grade and invasion. Current evidence supports endoscopic management in carefully selected low-risk and intermediate-risk cases, but comparison with nephroureterectomy is limited by retrospective data and selection bias.

Adjuvant treatment and surveillance

After complete endoscopic removal, a single instillation of chemotherapy or immunotherapy through a ureteric catheter may be considered to reduce recurrence. Mitomycin and BCG are the agents most often discussed, but evidence for their routine use after upper tract resection remains weaker than the evidence for similar treatment in bladder cancer. Renal impairment, prior urothelial cancer, infection risk and the expected benefit all influence the decision, while adjuvant chemotherapy has no established universal role after complete endoscopic resection.

Surveillance should be planned according to the original tumour and final pathology. It may include urine cytology, upper tract imaging, ureteroscopy and cystoscopy. Low-grade localised disease may be managed with active surveillance in selected patients, whereas invasive or high-grade disease usually requires earlier escalation. Follow-up must be reliable, since delaying treatment for a recurrent lesion can reduce the opportunity to preserve kidney function.

For persistent pain or fatigue after treatment, clinicians consider multiple causes, and general background on inflammation without infection can help separate an immune response from a proven bacterial cause. Such information does not replace evaluation for infection, obstruction or recurrence, but it supports more precise assessment when symptoms persist without an obvious infectious source.

Safety and escalation when endoscopy fails

Endoscopic treatment carries risks including bleeding, ureteric perforation, infection, acute kidney injury and later ureteric stricture. Protective measures include careful tissue handling, controlled laser energy, adequate drainage and antibiotics when indicated. Patients should receive clear advice about fever, worsening pain, reduced urine output or persistent haematuria, as some complications require urgent review.

Failure to remove all visible tumour, a finding of invasive disease or repeated recurrence usually prompts reconsideration of nephroureterectomy. When disease later involves the bladder or cannot be controlled endoscopically, radical cystectomy may enter the discussion. A patient-facing overview of radical cystectomy risks is useful when comparing a more extensive operation with its recovery implications.

Evidence and delivery in Australia

Australian urologists may draw on guidance from the Urological Society of Australia and New Zealand, the American Urological Association and the European Association of Urology. These recommendations recognise kidney-preserving endoscopy while emphasising careful pathology, complete resection and close follow-up. No single technique suits every tumour, and treatment centres should explain where evidence is observational, where practice is variable and where an approach remains investigational.

Tertiary urology services and much of the private hospital market offering advanced endoscopic equipment are concentrated in capital cities such as Sydney, Melbourne and Brisbane. Medicare covers consultations and much of the care delivered in public hospitals, while private insurance and out-of-pocket payments may apply in private facilities. Access to particular lasers, imaging and specialist pathology can vary, so patients should confirm that the full treatment pathway is locally available.

Outside metropolitan centres, patients in regional Western Australia, the Northern Territory and northern Queensland may need to travel to a tertiary service for diagnosis or treatment. Telehealth can support planning and follow-up, but it does not replace the need for ureteroscopy, imaging or urgent treatment. Work schedules, long-distance travel and delayed referral may complicate care, making clear communication between local clinicians and city-based specialists particularly important.

Regulation also shapes treatment access. The Therapeutic Goods Administration assesses many medicines and medical devices used in Australia, with procurement and clinician credentialing determining which technologies are available locally. The Privacy Act 1988 and Australian Privacy Principles govern how many organisations handle health information. For people exposed to aromatic amines in industries such as dye, rubber, textile or leather manufacturing, the Work Health and Safety Act 2011 places duties on employers to assess and manage workplace risks.

Practical recommendations and next steps

A useful treatment discussion should cover diagnostic certainty, tumour biology, kidney function and the consequences of both endoscopic treatment and surgery. Patients benefit from knowing which parts of the plan are established, which depend on individual risk and which treatments remain experimental.

• Choose a centre with experienced upper tract endoscopy, appropriate imaging and access to specialist pathology.
• Confirm the diagnosis and stage before choosing between observation, repeated endoscopic treatment and nephroureterectomy.
• Weigh kidney-preserving treatment against standard cancer surgery using the tumour’s grade, size, location and completeness of resection.
• Establish an adjuvant treatment plan, including the reason for using mitomycin, BCG or another agent.
• Arrange risk-based surveillance with urine testing, imaging, endoscopy and a named clinician responsible for follow-up.
• Prepare for practical issues such as travel, time away from work, drainage devices and possible emergency readmission.

If a renal pelvic or ureteral lesion is suspected or has been diagnosed, contact a urology service promptly and request an upper tract cancer assessment. Bring imaging, urine results, pathology reports, medication details and information about kidney function. Call the urology unit, ask for the upper-tract cancer pathway and use the appointment to secure a coordinated plan for treatment, recovery and long-term surveillance.